Last reviewed · How we verify

NCT06741514

A Study of Precice Intramedullary Limb Lengthening System (IMLL) Limb Lengthening Procedures

ENROLLING BY INVITATION Last updated 18 December 2025
What this trial tests

trial testing Precice IMLL in Limb Length Discrepancy in 100 participants. Enrolling by invitation.

Timeline
25 March 2024
Primary endpoint
1 July 2026
30 December 2026

Quick facts

Lead sponsorNuVasive
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment100
Start date25 March 2024
Primary completion1 July 2026
Estimated completion30 December 2026
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

NuVasive — full company profile →

Who can join

Eligibility, any sex, with Limb Length Discrepancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Sponsor is conducting a survey to understand how parents or legal guardians feel about the benefits of using the Precice IMLL System to lengthen limbs in children who are 12 years old or younger.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other NuVasive trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06741514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing